stockportfolio.pro
Stocks / NVCR vs ZLAB
NVCR vs ZLAB
NovoCure Limited and Zai Lab Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| NovoCure Limited (NVCR) | Zai Lab Limited (ZLAB) | |
|---|---|---|
| Market cap | $1.9B | $1.9B |
| Revenue (latest FY) | $655.35M | $460.16M |
| Net income (latest FY) | $-136.23M | $-175.54M |
| Revenue growth (5y CAGR) | 5.8% | 56.5% |
| Net margin | -20.8% | -38.1% |
| Return on equity | -40.0% | -24.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NVCR — free Open ZLAB — freeFrequently asked questions
Which is bigger, NVCR or ZLAB?
NovoCure Limited is larger by market capitalization — $1.9B versus $1.9B.
Which grows faster, NVCR or ZLAB?
Over the last five fiscal years, Zai Lab Limited grew revenue faster — 56.5%/yr versus 5.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.